Drug Administration Schedule

Publication Title: 
Malaria Journal

BACKGROUND: The efficacy of artemisinin-based combination therapy has already been demonstrated in a number of studies all over the world, and some of them can be regarded as comparably effective. Ease of administration of anti-malarial treatments with shorter courses and fewer tablets may be key determinant of compliance. METHODS: Patients with uncomplicated falciparum malaria and over six months of age were recruited in Cameroon, Mali, Rwanda and Sudan.

Author(s): 
Sagara, Issaka
Rulisa, Stephen
Mbacham, Wilfred
Adam, Ishag
Sissoko, Kourane
Maiga, Hamma
Traore, Oumar B.
Dara, Niawanlou
Dicko, Yahia T.
Dicko, Alassane
Djimde, Abdoulaye
Jansen, F. Herwig
Doumbo, Ogobara K.
Publication Title: 
Malaria Journal

BACKGROUND: Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated falciparum malaria. Artemether-lumefantrine (AL), a fixed dose co-formulation, has recently been approved for marketing in India, although it is not included in the National Drug Policy for treatment of malaria. Efficacy of short course regimen (4 x 4 tablets of 20 mg artemether plus 120 mg lumefantrine over 48 h) was demonstrated in India in the year 2000.

Author(s): 
Valecha, Neena
Srivastava, Prakriti
Mohanty, Suman S.
Mittra, Pooja
Sharma, Surya K.
Tyagi, Prajesh K.
Pradhan, Khageswar
Dev, Vas
Singh, Ruchi
Dash, Aditya P.
Sharma, Yagya D.
Publication Title: 
Malaria Journal

BACKGROUND: Drug resistance in Plasmodium falciparum poses a major threat to malaria control. Combination anti-malarial therapy, including artemisinins, has been advocated to improve efficacy and limit the spread of resistance. The fixed combination of oral artemether-lumefantrine (AL) is highly effective and well-tolerated. Artemisinin/naphtoquine (AN) is a fixed-dose ACT that has recently become available in Africa.

Author(s): 
Toure, Offianan A.
Pénali, Louis K.
Yapi, Jean-Didier
Ako, Berenger A.
Toure, Walamtchin
Djerea, Kali
Gomez, Genevieve O.
Makaila, Oyewole
Publication Title: 
Malaria Journal

Artemisinin, from which the artemether component of Coartem (artemether/lumefantrine, AL) is derived, is obtained from the plant sweet wormwood (Artemisia annua) which has been used for over 2,000 years as a Chinese herbal remedy. Artemisinin was first identified by Chinese researchers as the active anti-malarial constituent of A. annua and its derivatives were found to be the most potent of all anti-malarial drugs. Artemether acts rapidly, reducing the infecting parasite biomass by approximately 10,000-fold per asexual life cycle.

Author(s): 
Premji, Zulfiqarali G.
Publication Title: 
Malaria Journal

Artemether and lumefantrine (AL), the active constituents of Coartem exhibit complementary pharmacokinetic profiles. Artemether is absorbed quickly; peak concentrations of artemether and its main active metabolite, dihydroartemisinin (DHA) occur at approximately two hours post-dose, leading to a rapid reduction in asexual parasite mass and a prompt resolution of symptoms.

Author(s): 
Djimde, Abdoulaye
Lefèvre, Gilbert
Publication Title: 
Malaria Journal

Infants and children under five years of age are the most vulnerable to malaria with over 1,700 deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed paediatric anti-malarial formulations available. Artemisinin-based combination therapy is the current standard of care for patients with uncomplicated falciparum malaria in Africa. Artemether/lumefantrine (AL) meets WHO pre-qualification criteria for efficacy, safety and quality.

Author(s): 
Abdulla, Salim
Sagara, Issaka
Publication Title: 
Malaria Journal

BACKGROUND: Whiles awaiting for the arrival of an effective and affordable malaria vaccine, there is a need to make use of the available control tools to reduce malaria risk, especially in children under five years and pregnant women. Intermittent preventive treatment (IPT) has recently been accepted as an important component of the malaria control strategy.

Author(s): 
Ahorlu, Collins K.
Koram, Kwadwo A.
Seakey, Atsu K.
Weiss, Mitchell G.
Publication Title: 
Malaria Journal

BACKGROUND: The efficacy of amodiaquine (AQ), sulphadoxine-pyrimethamine (SP) and the combination of SP+AQ in the treatment of Cameroonian children with clinical malaria was investigated. The prevalence of molecular markers for resistance to these drugs was studied to set the baseline for surveillance of their evolution with time.

Author(s): 
Mbacham, Wilfred F.
Evehe, Marie-Solange B.
Netongo, Palmer M.
Ateh, Isabel A.
Mimche, Patrice N.
Ajua, Anthony
Nji, Akindeh M.
Irenee, Domkam
Echouffo-Tcheugui, Justin B.
Tawe, Bantar
Hallett, Rachel
Roper, Cally
Targett, Geoffrey
Greenwood, Brian
Publication Title: 
Malaria Journal

BACKGROUND: Artemisinin-based combination therapy (ACT) is presently recommended by the World Health Organization as first-line treatment for uncomplicated Plasmodium falciparum malaria in several countries, as a mean of prolonging the effectiveness of first-line malaria treatment regimens.

Author(s): 
Congpuong, Kanungnit
Bualombai, Pongwit
Banmairuroi, Vick
Na-Bangchang, Kesara
Publication Title: 
Malaria Journal

BACKGROUND: Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability. MATERIALS AND METHODS: A prospective study was carried out to document the adherence to and acceptability of AL administration. This was undertaken in the context of the ALIVE study, a prospective, community-based, observational study in a rural, malaria-endemic area of Tanzania. Following microscopic confirmation of P.

Author(s): 
Kabanywanyi, Abdunoor M.
Lengeler, Christian
Kasim, Prudensiana
King'eng'ena, Said
Schlienger, Raymond
Mulure, Nathan
Genton, Blaise

Pages

Subscribe to RSS - Drug Administration Schedule